Ensysce Biosciences Q2 net loss widens on higher R&D costs

Ensysce Biosciences

13/08/2026 21:25

Overview
US biotech firm's Q2 net loss widened yr/yr on higher R&D expenses
Company completed Cy Biopharma acquisition post-quarter, adding CY200 for complex pain
Acquisition and financings provided about $31 mln post-quarter cash boost

Outlook
Company expects cash runway into late 2027, extendable to 2028 if milestones met
Ensysce plans to advance CY200 through Phase 2 trial and prepare for registrational development
Company expects continued losses as research and development efforts continue

Result Drivers
HIGHER R&D SPENDING - Co said increased clinical activity for PF614 drove higher research and development expenses in Q2
LOWER GRANT FUNDING - Co said Q2 federal grant funding fell due to timing of eligible research activities under the MPAR grant

Company press release: ID:nACS4nNrba

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.20
 
Q2 Net Loss
 
$2.60 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Ensysce Biosciences Inc is $8.25, about 1,969.2% above its August 12 closing price of $0.40

Reuters Recommended Reads
Aug 12 - Turn Therapeutics Q2 net loss per share widens on higher R&D costs
Aug 12 - Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aug 13 - Kodiak Sciences Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)